suPARnostic® as a treatment efficacy monitoring tool in systemic inflammatory response syndrome/sepsis patients
© Eugen-Olsen et al; licensee BioMed Central Ltd. 2008
Published: 18 November 2008
Biomarkers may aid in risk triaging of systemic inflammatory response syndrome (SIRS) patients at admittance to hospital and in the monitoring of response to medical intervention. The overall aim is reducing mortality in SIRS and sepsis patients.
A prospectively collected cohort of patients with SIRS that were admitted to an emergency department and a department of infectious diseases at a Copenhagen University hospital were studied. Samples obtained daily during hospitalization were measured for soluble urokinase plasminogen activator receptor (suPAR) using the CE/IVD-approved (the product complies with the European Directives for In-Vitro Diagnostics) suPARnostic® assay and were compared with various other clinical parameters associated with assessing disease severity, including C-reactive protein, procalcitonin, Simplified Acute Physiology Score II, and Sepsis-related Organ Failure Assessment scores. Survival was assessed using receiver operating curve statistics.
The suPARnostic® assay provided significant information on risk of mortality following admission. Continuous elevated suPAR levels during treatment were associated with poor clinical outcome.
This article is published under license to BioMed Central Ltd.